INS and fatty liver disease: Gut-derived SCFAs promote insulin sensitivity, reduce adiposity and body weight [101–105] and downregulate PPARα, increasing oxidative metabolism in the liver and adipose tissue and thus lowering fat accumulation, and hepatic steatosis and increasing insulin sensitivity [88, 101].